Taken together, the data presented here illustrate that insulin therapy may seem as more appropriate than other anti-DM pharmacotherapies in the management of COVID-19 patients with DM due to the lower risk of uncontrolled hyperglycemia and reduced propensity to develop diabetic ketoacidosis (DKA). Here, INS is linked to diabetes mellitus.